Browse
Submit Data
Databases
API
Help

Dataset Information

6 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Study Assessing the Interchangeability Between TRS003 and Bevacizumab For CRC

ABSTRACT: This is a Phase 3, multicenter, randomized and double-blind study assessing the interchangeability between TRS003 and China-approved Bevacizumab (also called China-approved Avastin) for first-line treatment of patients with metastatic Colorectal Cancer (CRC), approximately 126 patients will be enrolled in this study. Patients who sign the informed consent, meet the eligibility criteria and are confirmed as non-progressors after lead-in treatment period with Bevacizumab in combination with modified FOLFOX6 chemotherapy for 6 cycles, will be randomized (1:1) to either the non-switching arm and receive Bevacizumab + modified FOLFOX6 for all subsequent cycles or to the switching arm and receive TRS003 alternating with Bevacizumab in combination with mFOLFOX6 until disease progression or intolerability.

DISEASE(S): Colorectal Neoplasms,Metastatic Colorectal Cancer (crc)

PROVIDER: 2730925 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phase II clinical trial of the first-line Stop-and-Go modified FOLFOX6 and bevacizmab for patients with unresectable/recurrent colorectal cancer

Project description:Interventions: After 8 cycles of modified FOLFOX 6 with bevacizmab, patients receive sLV5FU2 with bevacizumab (until 8 cycles are completed or disease progression). And then, patients receive modified FOLFOX6 with bevacizmab (until 8 cycles are completed or disease progression.) Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2616726 | ecrin-mdr-crc

Randomized phase 2 study of mFOLFOX6 plus bevacizumab versus modified OPTIMOX plus bevacizumab for metastatic colorectal cancer

Project description:Interventions: After 8 cycles of mFOLFOX 6 plus bevacizumab, patients receive UFT/LV with bevacizumab (until 5 cycles are completed or disease progression). And then, patients receive modified FOLFOX6 plus bevacizumab until disease progression. Patients receive mFOLFOX6 plus bevacizumab until disease progression. Primary outcome(s): disease control survival Study Design: Parallel Randomized

| 2618936 | ecrin-mdr-crc

Prediction of response to FOLFOX

Project description:The patients who underwent surgery for primary lesions were examined. All patients had metastatic or recurrent CRC and received modified FOLFOX6. Responders and nonresponders were determined based on the best observed response at the end of the first-line treatment, mFOLFOX6. Gene-expression profiles of primary CRC were determined using Human Genome GeneChip arrays U133. Colorectal cancer patients who had undergone surgical resection of colorectal cancer were studied. To identify molecular signatures to predict response to mFOLFOX6 regimen, gene expression profiles were compared between Reponder and Non-responder. Some patients are overlapped with Bevacizumab therapy.

2013-01-03 | E-GEOD-19860 | biostudies-arrayexpress

Multicenter phase II study of modified FOLFOX6 and bevacizumab in chemonaive advanced or recurrent colorectal cancer.

Project description:Interventions: Patients receive modified FOLFOX6 with bevacizumab (Treatment will be continued to 24 cycles unless the disease progression, unacceptable toxicity, or consent withdrawal.). Primary outcome(s): Efficacy: Response rate Study Design: Single arm Non-randomized

| 2616982 | ecrin-mdr-crc

Preventive effect of shakuyaku-kanzo-to on neurotoxicity of FOLFOX plus bevacizumab for patients with metastatic colorectal cancer: a prospective phase II study

Project description:Interventions: Patients receive FOLFOX4 plus bevacizumab or modified FOLFOX6 plus bevacizumab and take shakuyaku-kanzo-to (7.5g/day) orally every day during FOLFOX plus bevacizumab treatment. Primary outcome(s): Neurotoxicity frequency of accumulation dose 500mg/m2 of oxaliplatin Study Design: Single arm Non-randomized

| 2617341 | ecrin-mdr-crc

Prediction of response to FOLFOX

2013-01-03 | GSE19860 | GEO

Rate of recurrent neutropenia between the omitted of bolus dose of fluorouracil group compare with the oxaliplatin dose reduction group in colorectal cancer patients, a randomized cross-over trial

Project description:Interventions: an omitted of bolus dose of fluorouracil of modified FOLFOX6 regimen,reduction of oxaliplatin dose of modified FOLFOX6 regimen, from 85 to 65 milligram per square meter;Experimental Drug,Active Comparator Drug;an omitted of bolus dose of 5-FU group,an oxaliplatin reduction group Primary outcome(s): rate of recurrent neutropenia within 2 cycles of chemotherapy (mFOLFOX6 regimen) rate Study Design: Randomized

| 2568181 | ecrin-mdr-crc

Gene expression profile of FFPE samples collected with translational purposes from the MITO16/MaNGO-OV2 clinical trial

Project description:MITO16/MaNGO-OV2 (NCT01706120) is a multicenter, phase IV, single arm trial for advanced stage IIIB-IV or recurrent, previously untreated, ovarian cancer patients receiving carboplatin, paclitaxel plus bevacizumab for six 3-weekly cycles followed by bevacizumab single agent until progression or unacceptable toxicity up to a maximum of 22 total cycles. The trial that was specifically designed with a translational primary endpoint to explore if selected clinical and biological factors could identify ovarian cancer patients with better prognosis in terms of progression free survival and overall survival after combined first-line treatment with chemotherapy plus Bevacizumab. The translational study, designed together with the clinical trial, the translational study implicated the collection of patients’ tissue (formalin-fixed paraffin-embedded – FFPE) and blood samples. Gene expression profile was among the molecular analyses proposed on FFPE samples.

2023-04-19 | GSE208103 | GEO

Liver resection after chemotherapy for liver only metastasis from colorectal cancer

Project description:Interventions: Chemotherapy with modified FOLFOX6 plus BV(bevacizumab). Treatment repeats every 14 days for up to 6 courses (5 courses for BV) in the absence of disease progression or unacceptable toxicity. Liver resection (if possible, 4 to 8 weeks after modified FOLFOX6 plus BV) Primary outcome(s): Curative resection rate (R0 resection rate) [in all subjects] Study Design: Single arm Non-randomized

| 2617582 | ecrin-mdr-crc

FinHER trial : Patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer

Project description:The FinHER trial is a multicentre phase 3 randomised adjuvant breast cancer trial that enrolled 1010 patients. The women were randomly assigned to receive three cycles of docetaxel or vinorelbine, followed by three cycles of fluorouracil, epirubicin, and cyclophosphamide.

2016-02-02 | GSE65095 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data